Stocktoria
Neumora Therapeutics, Inc. NMRA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2023-09-15
Neumora Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D expense | $176.1M | $200.9M | $142.7M | $91.7M |
| Operating income | -$241.2M | -$263.5M | -$252.1M | -$135.9M |
| Interest expense | $2.0M | — | — | — |
| Income tax | $130,000 | $178,000 | $268,000 | — |
| Net income | -$236.9M | -$243.8M | -$235.9M | -$130.9M |
| EPS (diluted) | $-1.45 | $-1.53 | $-3.63 | $-4.81 |
| Operating cash flow | -$206.4M | -$182.9M | -$163.3M | -$114.9M |
| Free cash flow | — | — | -$163.4M | -$115.4M |
| Cash & equivalents | $182.5M | $142.1M | $374.0M | $240.9M |
| Total assets | $191.0M | $317.0M | $496.2M | $426.2M |
| Total liabilities | $87.2M | $29.9M | $27.1M | $29.4M |
| Shareholders' equity | $103.9M | $287.1M | $469.1M | -$446.9M |
Source: SEC EDGAR filings · CIK 0001885522 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.